The present invention generally relates to 2,3-Disubstituted pyrido[3,4-b]pyrazine-containing compounds as a kinase inhibitor and methods of uses thereof. Pharmaceutical compositions and methods for treating those kinase related diseases are within the scope of this invention.

Disclosed herein are double payload antibody-drug conjugates (ADCs) and compositions comprising ADCs and one or more pharmaceutically acceptable carriers. Also, disclosed herein are methods for using these ADCs and compositions comprising ADCs and one or more pharmaceutically acceptable carriers to treat various cancers. Also disclosed herein are kits comprising compositions comprising ADCs.

Disclosed herein are double payload antibody-drug conjugates (ADCs) and compositions comprising ADCs and one or more pharmaceutically acceptable carriers. Also, disclosed herein are methods for using these ADCs and compositions comprising ADCs and one or more pharmaceutically acceptable carriers to treat various cancers. Also disclosed herein are kits comprising compositions comprising ADCs.

Disclosed is an organometallic compound represented by a following Chemical Formula I, wherein the compound is a metal complex including a central coordination metal and a main ligand binding thereto, wherein the main ligand has a structure in which a fused ring is further introduced into 2-phenylquinoline. When the organometallic compound is used as dopant of a light-emitting layer of an organic electroluminescent device, rigidity is imparted to the organometallic compound molecule such that a full width at half maximum (FWHM) is narrow and thus color purity is improved. Further, a non-luminescent recombination process is reduced such that luminous efficiency and lifespan of the organic electroluminescent device are improved. Chemical Formula I is shown below:

##STR00001##

The present invention relates to compounds according to general formula (I)

##STR00001##

which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.

The present invention relates to compounds according to general formula (I)

##STR00001##

which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.

A tetracyclic compound as a Cdc7 inhibitor. Specifically disclosed is a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.

##STR00001##

A tetracyclic compound as a Cdc7 inhibitor. Specifically disclosed is a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.

##STR00001##

An organic electroluminescence device includes an anode, a cathode, and an emitting layer disposed between the anode and the cathode. The emitting layer comprises a delayed fluorescent compound M2 having at least one deuterium atom and a compound M3 having at least one deuterium atom. A singlet energy S.sub.1(M2) of the compound M2 and a singlet energy S.sub.1(M3) of the compound M3 satisfy the relationship S.sub.1(M3)>S.sub.1(M2).

An organic electroluminescence device includes an anode, a cathode, and an emitting layer disposed between the anode and the cathode. The emitting layer comprises a delayed fluorescent compound M2 having at least one deuterium atom and a compound M3 having at least one deuterium atom. A singlet energy S.sub.1(M2) of the compound M2 and a singlet energy S.sub.1(M3) of the compound M3 satisfy the relationship S.sub.1(M3)>S.sub.1(M2).